Wockhardt revenue rises 24% as higher costs limit profit growth
In short
Wockhardt said its September-quarter revenue rose 24%, helped by strong biotech and emerging-market growth. But higher costs pushed down operating margins and kept profit growth weak.
This matters because the company is growing sales, but expenses are eating into the gain. The reporting does not give the exact profit number or say how investors reacted.
What the reporting says
Wockhardt reported a 24% rise in September-quarter revenue, helped by strong biotech and emerging-market growth, while higher costs reduced operating margins and kept profit growth weak. The publisher-supplied summary does not give the exact profit figure or margin level, and it does not specify which costs increased. The immediate market reaction is not stated in the available reporting.
Why it matters
Wockhardt reported a 24% jump in September-quarter revenue, with the publisher-supplied summary pointing to biotech and emerging-market strength. At the same time, higher costs weighed on operating margins and prevented stronger profit growth. That makes the result mixed: sales momentum improved, but profitability did not keep pace. The available reporting does not identify the specific cost drivers or any immediate share-price response.